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Statement of translational relevance: 
Surveillance duodenoscopy is undertaken in patients with familial 
adenomatous polyposis (FAP) or MUTYH-associated polyposis (MAP) to 
reduce the risk of duodenal cancer. Current guidelines in the USA and Europe 
recommend that the screening interval and decisions on interventions are 
based upon Spigelman staging of duodenal polyposis. In this study we 
demonstrate a greater mutational burden in MAP than FAP duodenal 
adenomas despite lower Spigelman stage duodenal polyposis in the MAP 
patients studied.  These findings suggest that the risk of progression to cancer 
in the context of early stage duodenal polyposis could be higher in MAP than 
FAP patients and challenge the assumption that the same surveillance 
protocols should be applied in MAP and FAP.  
 
 
Abstract 
 
Purpose: Duodenal polyposis and cancer are important causes of morbidity 
and mortality in familial adenomatous polyposis (FAP) and MUTYH-
associated polyposis (MAP). This study aimed to comprehensively 
characterize somatic genetic changes in FAP and MAP duodenal adenomas 
to better understand duodenal tumorigenesis in these disorders. 
Experimental Design: Sixty-nine adenomas were biopsied during endoscopy 
in 16 FAP and 10 MAP patients with duodenal polyposis. Ten FAP and 10 
MAP adenomas and matched blood DNA samples were exome sequenced, 
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42 further adenomas underwent targeted sequencing and 47 were studied by 
array comparative genomic hybridization. Findings in FAP and MAP duodenal 
adenomas were compared to each other and to the reported mutational 
landscape in FAP and MAP colorectal adenomas. 
Results: MAP duodenal adenomas had significantly more protein-changing 
somatic mutations (P = 0.018), truncating mutations (P = 0.006) and copy 
number variants (P = 0.005) than FAP duodenal adenomas, even though 
MAP patients had lower Spigelman stage duodenal polyposis. Fifteen genes 
were significantly recurrently mutated. Targeted sequencing 
of APC, KRAS, PTCHD2 and PLCL1 identified further mutations in each of 
these genes in additional duodenal adenomas. In contrast to MAP and FAP 
colorectal adenomas, neither exome nor targeted sequencing 
identified WTX mutations (P=0.0017). 
Conclusions: The mutational landscapes in FAP and MAP duodenal 
adenomas overlapped with, but had significant differences to those reported 
in colorectal adenomas. The significantly higher burden of somatic mutations 
in MAP than FAP duodenal adenomas despite lower Spigelman stage 
disease could increase cancer risk in the context of apparently less severe 
benign disease.  
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Introduction 
 
Familial adenomatous polyposis (FAP) and MUTYH-associated polyposis 
(MAP) are inherited disorders characterized by colorectal polyposis and 
cancer. They are also associated with extra-colonic manifestations including 
polyposis and cancer in the upper gastrointestinal tract, most notably 
duodenal disease that has become an important cause of morbidity and 
mortality as the management of colorectal disease has improved (1).  A 
recent study of FAP estimated the lifetime risk of duodenal polyposis to be 
88% and of cancer to be 18% (2). In a multicenter retrospective study of MAP, 
duodenal polyps were noted in 26 of 150 (17%) patients undergoing 
duodenoscopy and the lifetime risk of duodenal cancer was estimated at 4% 
(3). A more recent study in two specialist centers identified duodenal 
adenomas in 31 of 92 (34%) MAP patients undergoing endoscopy at a 
median age of 50 years (4). 
 
In patients with FAP or MAP regular endoscopic surveillance of the duodenum 
has been advocated from the age of 25-30 years (1). Spigelman staging 
based upon the number, size, dysplasia and presence of villous histology of 
adenomas was developed to better define the severity of duodenal disease in 
FAP (5) and is recommended to guide the frequency of surveillance, stratify 
cancer risk and inform decisions about surgical intervention (6). Duodenal 
disease in FAP appears to progress slowly through Spigelman stages (0-IV) 
with an associated increase in cancer risk (7). The natural history of duodenal 
polyposis in MAP is not well defined but there are reports of duodenal cancer 
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occurring in the context of minimal background polyposis (3,8). More evidence 
is required to support or refute current recommendations to apply the same 
Spigelman stage-based surveillance and intervention for MAP as FAP (1,6).  
 
Rapid recurrence of duodenal adenomas has been reported following 
endoscopic polypectomy in patients with FAP (9,10). Surgical treatments 
including ampullectomy, duodenectomy and pancreatico-duodenectomy 
appear effective for cancer prevention but are associated with significant 
procedure-associated risks (7,11). Medical treatment using the 
cyclooxygenase (COX) inhibitors sulindac and celecoxib has proven less 
effective in the duodenum than the colorectum (12–15) but a recent trail of 
combined COX and epidermal growth factor receptor inhibition with sulindac 
and erlotinib demonstrated promising short-term effects on duodenal polyp 
burden (16). The efficacy of medical and surgical treatment or prevention of 
duodenal disease in MAP remains unknown.  
In colorectal tumorigenesis, the nature and positions of APC mutations appear 
to determine a critical level of over-activation of β-catenin signaling that leads 
to a failure in cell growth control without induction of apoptosis (17), a 
scenario described by the “just right” hypothesis (18). The situation in FAP-
associated upper gastrointestinal tumors appears to be subtly different as 
somatic APC mutations cluster in a more 3’ region (19). Severe upper 
intestinal polyposis is also associated with a more 3’ location of inherited APC 
mutations (19).  
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Recently, a comprehensive survey of the mutational landscape of colorectal 
adenomas from patients with FAP and MAP was made using exome 
sequencing (20). This confirmed the importance of somatic APC and KRAS 
mutations as drivers of early colorectal tumorigenesis in both disease settings. 
It also identified frequent somatic mutations of WTX (also known as FAM123B 
and AMER1) as had been reported previously in sporadic colorectal cancer 
(21) and that, like APC mutations, may act through deregulation of β-catenin 
turnover.  Although comprehensive molecular genetic studies of duodenal 
adenomas or carcinomas in patients with FAP have not been reported, 
targeted sequencing has confirmed a role for APC and revealed oncogenic 
mutations of KRAS in 9-30% of FAP duodenal adenomas (22–25). 
Comparable studies of MAP-associated duodenal tumors have not been 
reported.  
 
In this study we applied whole exome and targeted Sanger sequencing and 
array comparative genomic hybridization (aCGH) to characterize somatic 
genetic variation associated with the development of duodenal adenomas in 
patients with FAP and MAP.  
 
Materials and Methods 
 
Patients and Samples 
 
Ethical approval was granted by the UK NHS Research Ethics Committee 
system (reference 10/MRE093). All patients provided written informed 
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consent. This study was completed in accordance with the ethical guidelines 
of the Declaration of Helsinki. Their diagnoses of FAP or MAP were confirmed 
by genetic testing. Biopsies of approx. 3mm of duodenal polyps were taken 
during upper GI surveillance endoscopy. Spigelman stage was calculated 
using the method described by Saurin et al (26). A blood sample was taken 
for automated DNA extraction. A small section of each biopsy was formalin 
fixed and histopathological classification, dysplasia by the Vienna 
classification (27) and proportion of adenomatous material were determined. 
For the latter, the percentage of epithelial adenoma nuclei was determined in 
relation to the total number of nuclei comprising adenoma, non-neoplastic 
crypts, stroma / lamina propria / muscularis mucosae / submucosa, lymphoid 
and inflammatory cells. The remainder of each biopsy was snap frozen with 
liquid nitrogen and stored at -80°C until DNA was extracted using the 
phenol/chloroform method. A potential limitation in sample characterization 
was that we could not confirm whether sections used for histopathology were 
representative of the rest of each biopsy. 
 
Whole Exome Sequencing  
 
Whole exome sequencing of adenoma and matched blood DNA was 
performed to a mean depth of coverage of 100x at the Beijing Genomics 
Institute, Hong Kong, using the SureSelect Human 50Mb capture kit (Agilent) 
and Illumina platforms. A potential limitation of the chosen depth of coverage 
is failure to detect somatic variants occurring at very low frequency due to 
tumor heterogeneity. 
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Bioinformatic Analysis and Identification of Somatic Single Nucleotide 
Variants (SNVs).  
 
Details of variant calling can be found in the suppl methods. 
  
Validation of Somatic Mutations  
 
Putative protein changing somatic mutations were validated by PCR and 
Sanger sequencing of original adenoma DNA samples. When the sequencing 
depth in a matched blood sample was 20x or less, PCR and Sanger 
sequencing was also performed on the blood DNA sample. Primers were 
purchased from Eurofins and PCR was completed as described in the 
supplementary methods.  
 
Identification and Analysis of Recurrently Mutated Genes 
 
Recurrently mutated genes were defined as those with ≥2 validated somatic 
protein changing mutations in the 20 duodenal adenoma exomes. Data for 
adenomas 37A1 and 37A4 and for adenomas 24A3 and 24A8 were merged 
as each of these pairs shared a significant proportion of confirmed somatic 
mutations indicating that they were not independent tumors. Mutations 
present in each of these pairs were counted only once. To determine which 
genes were significantly mutated, all validated variants were analyzed using 
MutSig v1.0 (http://www.broadinstitute.org/cancer/cga/mutsig). To adjust for 
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multiple testing and reduce the false discovery rate, q values were calculated 
(32). Genes with P< 0.05 (Fishers Exact test) and a Q<= 0.1 were reported as 
significantly mutated (see supplementary methods for details). 
 
In order to gain insight into potential mechanisms of tumorigenesis, pathway 
enrichment analysis was undertaken on all 941 validated somatic mutations 
using ConsensusPathDB (33) (suppl methods). 
 
Sanger Sequencing in Additional Adenomas 
 
Sanger sequencing of 42 additional adenoma biopsies was used to extend 
data on somatic mutations in ERBB3, KRAS, PLCL1, PTCHD2 and WTX and 
of 49 additional adenomas for APC exon 15 (for details see supplementary 
methods).  
 
Loss of Heterozygosity (LOH) Analysis  
 
LOH analysis at the APC locus was performed on adenomas in which somatic 
APC mutations were not identified by sequencing (details in supplementary 
methods). A 50% or greater reduction in an allele relative to constitutional 
DNA was reported as allelic loss. 
 
Identification and Confirmation of Somatic Copy Number Variants (CNVs) 
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Somatic CNVs were identified by aCGH of 47 duodenal adenomas, 26 from 
FAP patients and 21 from MAP patients, and matched blood DNA using the 
BlueGnome CytoChip ISCA 8x60k (v2.0) array (GRCh37) (supplementary 
methods). Slides were scanned at 3m resolution and data were analyzed 
using CytoGenomics software (Agilent). Each putative CNV was confirmed by 
either independent aCGH analysis using the Illumina CytoSNP-850k v1.0 chip 
and data analysis with BlueFuse Multi v3.3 or by quantitative (qPCR) using 
the 7500 Real-Time PCR system (Applied Biosystems) (supplementary 
methods). CNVs found by aCGH in samples that had been exome sequenced 
were also validated from exome data using ExomeCNV software (34) 
(supplementary methods). 
 
Published Data on Somatic APC Mutations in MAP and FAP Adenomas 
 
We compiled a database of somatic APC mutations reported in FAP or MAP 
duodenal or colorectal adenomas via a literature search in PubMed and 
Google using the search terms  'duodenum', 'colorectum', 'FAP', 'MAP' 
and 'adenoma'.  
 
Statistical Analysis 
 
Statistical analysis was performed using R (version 3.0.2). The Student’s t-
test was employed to compare the frequencies of SNVs in FAP and MAP 
adenomas and Fisher's exact test to compare the frequencies of G>T 
transversions. A P value of less than 0.05 was considered statistically 
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significant. Correlation of adenoma size with number of SNVs and Spigelman 
stage with number of SNVs was analyzed by Pearson’s correlation coefficient 
where 1 is a perfect positive correlation, 0 is no correlation and -1 is a perfect 
negative correlation  
 
Results 
 
Characterization of Patients and Adenomas 
 
Biopsies of 72 apparently independent polyps were obtained (1 to 7 biopsied 
polyps per patient). Histology confirmed that 69 were adenomas including 42 
from 16 patients with FAP and 27 from 10 patients with MAP (Table 1). Two 
biopsies contained only normal mucosa and one only inflamed ampullary 
tissue.  MAP patients were significantly older than those with FAP (mean 55.0 
years versus 42.9 years, P = 0.006), but had significantly lower Spigelman 
stage disease (mode stage II versus IV, P = 0.031). Spigelman stage was 
also lower in MAP than FAP patients from whom adenomas were used for 
whole exome sequencing (stages II,II,II,II,III vs III,III,III,IV respectively). There 
was no significant difference in the size of biopsied adenomas from FAP and 
MAP patients (mean 6.93 mm, range 1-30 mm, SD 6.35 mm versus mean 
8.12 mm, range 1.5-25 mm, SD 6.14 mm, P = 0.4255) or in the size of FAP 
and MAP adenomas used for whole exome sequencing (mean 11.1 mm, 
range 2-25 mm, SD 7.5 mm versus mean 11.7 mm, range 3-25 mm, SD 8.26 
mm respectively, P = 0.867). All adenomas showed only low grade dysplasia 
and most had tubular morphology with 7/42 (17%) of FAP adenomas and 2/27 
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(7%) of MAP adenomas having a villous component (Table 1). The lower 
Spigelman grade of duodenal disease in MAP than FAP patients reflected 
smaller adenoma numbers and less frequent villous morphology. 
 
Somatic Mutation Landscape in FAP and MAP Duodenal Adenomas  
 
Whole exome sequencing of 20 duodenal adenomas, 10 from 4 patients with 
FAP and 10 from 5 patients with MAP, together with matched blood DNA 
identified 1449 putative protein altering somatic mutations. PCR and Sanger 
sequencing validated 941 of these (65%, Supplementary Table 1 and 2) 
including 28 APC mutations that were identified initially by manual inspection 
of the exome data and 913 variants in other genes. Eighty three percent of the 
validated mutations were nonsynonymous (missense) changes, 13% were 
stopgains, 2% were splice site mutations, 1% were frameshifts and one was a 
stoploss. There were significantly more validated protein changing somatic 
mutations in MAP relative to FAP adenomas (mean 71.6, SD 53.56, range 8-
167 vs mean 22.5, SD 13.25, range 1-44, P = 0.0115; t-test) (Suppl Figure 1 
and Supplementary Table 1). This equated to a mean of 1.43 validated 
protein changing mutations per Mb in MAP adenoma exomes compared to a 
mean of 0.44 per Mb in FAP adenoma exomes (Figure 1). The per-Mb rates 
of protein changing mutations were broadly comparable to those reported 
previously in non-hypermutated colorectal cancers (21) with MAP duodenal 
adenomas being towards the top end of the reported range and FAP 
duodenal adenomas towards the bottom. However, differences in sequencing 
and variant calling methods demand caution in such comparisons. The 
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proportion of truncating mutations was also significantly higher in MAP than 
FAP adenomas (P = 0.006). Of 716 mutations in MAP adenomas 481 (67%) 
were G>T transversions compared to 28/225 (12%) in FAP adenomas (P < 
2.2e-16; Fisher’s exact test), a finding consistent with failure of base excision 
repair to remove adenine bases mis-incorporated opposite 8-oxo-7,8-dihydro-
2’-deoxyguanosine (8-oxodG) in MAP adenomas. Pathway enrichment 
analysis of all validated mutated genes using ConsensusPathDB highlighted 
over-representation of gene sets involving ECM-receptor interaction networks 
(q=0.0125), ERBB (q=0.0125), BDNF (q=0.0174), PI3K/AKT (q=0.0287), EGF 
and FGF (q=0.0414) signaling pathways in FAP adenomas as well as 
significant enrichment for protein complexes that are part of canonical WNT 
(q=0.00516) and MAPK (q=0.00516) signaling cascades.  
In MAP adenomas, interrogation for protein complex-based sets showed an 
enrichment for epigenetic transcription regulators (q=0.00263) as well as 
molecules important in DNA repair pathways (q=0.031) and, consequently, 
over-representation of genes involved in the maintenance of DNA integrity. 
The number of mutations in different adenomas from the same individual 
varied greatly (Suppl. Figure 1).  
We also tested for a correlation between adenoma size and the number of 
confirmed somatic mutations. Although larger adenomas contained more 
mutations, this did not reach significance for either FAP adenomas (Pearson's 
product-moment correlation, r = 0.62, P = 0.054) or MAP adenomas (r = 0.36, 
P= 0.303).  
Despite appearing to be distinct at endoscopy, MAP adenomas 37A1 and 
37A4 shared the same somatic APC mutations and 30 other validated 
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somatic variants. A further 167 validated variants were not shared. MAP 
adenomas 24A3 and 24A8 also appeared distinct at endoscopy but shared 
the same somatic APC mutations and 60 other validated variants while 34 
validated variants were not shared. The proportions of adenomatous nuclei 
also differed between adenomas in these pairs (Table 1). Each pair was 
considered likely to have diverged from a single progenitor lesion and variants 
in each pair were counted only once in analyses to identify recurrently 
mutated genes. 
 
Recurrently Mutated Genes 
 
Sixty-two genes were mutated recurrently in the adenomas subject to whole 
exome sequencing (Supplementary Table 3) but analysis with MutSig v1.0, 
which evaluates the number of mutations observed in the context of gene size 
and the background mutation rate, showed that only 15 were mutated 
significantly more often than expected (Table 2). Of these, 12 were also 
mutated significantly in the COSMIC database of somatic mutations in cancer 
(http://cancer.sanger.ac.uk/cosmic) (Table 2). Truncating mutations were 
observed recurrently in APC, PIGA, TRPM1 and SYNE1 but only APC and 
PIGA were mutated significantly above the expected background rate. PIGA 
was not mutated significantly in COSMIC and therefore does not appear to be 
a driver gene in more extensively studied tumor types. 
 
Extended Analysis of APC, KRAS, PTCHD2, ERBB3, PLCL1 and WTX 
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To gain further insight into the frequencies and nature of mutations affecting 
examples of both established and novel candidate driver genes, we extended 
the analysis of APC (in 49 further duodenal adenomas) and KRAS, PTCHD2, 
ERBB3 and PLCL1 (in 42 further duodenal adenomas) by Sanger 
sequencing. PLCL1 was not significantly mutated according to MutSig v1.0, 
but the 4 PLCL1 mutations identified during exome sequencing clustered 
within a region spanning residues 440-547 and this clustering was significant 
((35) (P = 0.004). Although whole exome sequencing did not identify any 
mutations in WTX it was identified recently as a frequently mutated gene in 
FAP and MAP colorectal adenomas (20) and is also among the most 
frequently mutated genes in non-hypermutated colorectal cancer (21). We 
therefore also sequenced WTX in 42 further duodenal adenomas. 
 
Forty further APC mutations were identified by Sanger sequencing (Tables 1 
and 4) and LOH analysis revealed somatic loss affecting 3 further APC alleles 
in which sequencing was normal. As aCGH detected no CNVs at the APC 
locus the LOH appeared to be copy neutral. 
The somatic APC mutations and those reported in previous studies of FAP 
duodenal adenomas (see Supplementary Table 4) clustered 3’ to the third 
(last) β-catenin binding 20 amino acid repeat. This non-random clustering was 
highly significant (P = 9.11x10-10 by the method of Ye et al (35)) and different 
to the clustering of somatic APC mutations in FAP-associated colorectal 
adenomas (Supplementary Table 4) that occurs after the first and second 20 
amino acid repeats (P <3.72x10-16 and P <3.88x10-29). In FAP duodenal 
adenomas, 15 of the 30 APC mutations we identified were insertion of an A in 
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the A6 tract at codons 1554-6 (c.4659dupA; E1554fsX5). This mutation also 
accounted for 17/35 previously reported somatic APC mutations in FAP 
duodenal tumors but only 1/296 in FAP colorectal adenomas (Supplementary 
Table 4, P < 0.0001; Fisher’s exact test).  
In MAP duodenal adenomas where biallelic APC mutations were identified, 
significant clustering occurred between codons 1530 and 1576 (P = 1.25x10-
7) despite the presence of GAA sequences throughout the coding region that 
could be mutated to stop codons by G>T transversion with only one instance 
of E1554fsX5 observed (in the adenoma pair 37A1 and 37A4, Supplementary 
Table 4).  
 
We did not observe any somatic WTX mutations in 60 independent duodenal 
adenomas (Table 3). This was significantly different (P = 0.0038, Fisher’s 
exact test) to the findings reported by Rashid et al. (20) in FAP and MAP 
colorectal adenomas, where 17 truncating mutations were identified in 128 
adenomas, making WTX the most frequently mutated gene after APC. WTX 
forms a complex with APC, Axin and β-TrCP2 that degrades β-catenin. It is 
likely that the differences we observed between duodenal and colorectal 
adenomas in the positions or presence of APC and WTX mutations reflect 
different requirements for β-catenin signaling for tumorigenesis in these 
contexts. 
 
After APC, KRAS was the most frequently mutated gene in duodenal 
adenomas (12/60, 20%) and KRAS mutations were significantly more 
frequent in MAP than FAP adenomas (8/22 vs 4/38, P < 0.023, Fisher’s exact 
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test). Only 3/8 KRAS mutations in MAP duodenal adenomas were the c.34 
G:C>T:A (G12C) mutation that has been considered as a potential biomarker 
of MAP in patients with multiple colorectal adenomas (36). MAP patients 
whose adenomas harbored KRAS mutations appeared to have lower 
Spigelman stage polyposis than corresponding FAP patients (stages 
II,II,II,II,III in MAP vs II,IV,IV in FAP, Table 1). 
 
Six somatic PTCHD2 mutations were identified in 60 independent adenomas, 
3 by whole exome sequencing and 3 by sequencing of additional adenomas. 
Five had CADD scores above 20 (i.e. corresponding to the top 1% of 
substitutions in terms of predicted deleterious effects). Adenomas 3A2 and 
37A1 each contained two PTCHD2 mutations but one of those in 37A1 was 
unlikely to be of functional significance (Supplementary Table 5). Six 
independent PLCL1 mutations were also observed: 4 in whole exomes and 2 
following targeted sequencing. The latter 2 did not cluster with the others 
(Supplementary Table 5). All but one of the PLCL1 mutations had CADD 
scores above 20. No further mutations of ERBB3 were identified by analysis 
of the 42 additional adenomas but the 2 mutations identified during exome 
sequencing had CADD scores of 28.4 and 30 and are very likely to impact 
function (Supplementary Table 5). 
 
Array CGH 
 
Array CGH revealed 8 CNVs (5 losses and 3 gains) in 5 of 19 MAP duodenal 
adenomas (Table 4) compared to none in 26 FAP adenomas (P = 0.0052, 
Research. 
on August 11, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-1269 
 19 
Fisher’s exact test). All were confirmed by either quantitative PCR or by using 
a second array, the Illumina CytoSNP-850k v1.0. Several involved genes in 
the BMP/TGF-β signaling pathway: the deletion at 18q21.1 in adenoma 44A4 
included SMAD4 and that at 9q22 included ENG, while the 15q11.1-15q21.1 
gains in adenomas 23A3 and 23A4 included GREM1, a BMP antagonist.  
 
Discussion 
 
Duodenal polyposis and cancer present a major challenge in the clinical 
management of FAP and MAP, but remain understudied and poorly 
understood. This study is the first to characterize comprehensively the burden 
and pattern of somatic mutations in duodenal adenomas from patients with 
FAP or MAP. We found that MAP duodenal adenomas carried a significantly 
higher burden of somatic protein changing mutations, truncating mutations 
and CNVs than FAP duodenal adenomas even though MAP patients had 
lower Spigelman stage duodenal polyposis than FAP patients. The greater 
mutation burden in MAP adenomas appears to reflect defective base excision 
repair. Although longitudinal or prospective studies of duodenal polyposis in 
MAP have not been reported, case reports have highlighted the occurrence of 
duodenal cancer in MAP patients in the absence of advanced duodenal 
polyposis (3,8). These observations and our data suggest that current 
recommendations to manage MAP duodenal polyposis using Spigelman 
staging in the same way as for FAP (1,6) may not be appropriate. A low polyp 
count in a patient with MAP may be falsely reassuring and, in addition, we did 
not find a significant correlation between adenoma size and mutation burden. 
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Mutation burdens in some small MAP adenomas were among the highest we 
observed. Large, prospective clinical studies could provide a better evidence 
base for duodenal surveillance recommendations and intervention in MAP.  
 
Our data confirm the importance of APC and KRAS mutations as drivers of 
duodenal tumorigenesis in FAP and MAP but show that in contrast with the 
colorectum (20,21,37,38) WTX is not a significant driver gene in early 
duodenal tumorigenesis. Neither did we identify by exome sequencing any 
mutations in a number of known driver genes including NRAS, CTNNB1, 
FBXW7 and TP53 that were mutated recurrently in previous studies of 
sporadic or FAP-associated colorectal adenomas (37,39) and that are also 
mutated in sporadic duodenal adenocarcinomas (40,41). They may be 
mutated later in duodenal tumorigenesis. 
The somatic APC mutations we identified in FAP and MAP duodenal 
adenomas clustered 3’ to the mutation cluster region observed in FAP-
associated and sporadic colorectal adenomas and cancers. Groves et al (19) 
and Miyaki et al (42) have reported similar findings. These more 3’ mutations 
are predicted to lead to truncated APC proteins that retain 3 β-catenin binding 
20 AA repeats in the majority of duodenal tumors rather than either 1 or 2 
repeats as occurs in colorectal tumors. In FAP duodenal adenomas we found 
that 14/25 (56%) somatic APC mutations were ins A mutations at codons 
1554-6 (4661 G>GA c.4659dupA; E1554fxs4). This is consistent with data we 
compiled from previous reports in which this mutation accounted for 17/35 
mutations (49%). Although very uncommon in FAP colorectal adenomas 
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(1/296 mutations in the reports we identified, Supplementary Table 4), this 
mutation has been seen recurrently in colorectal adenomas from patients with 
attenuated FAP (43–45) where it appears to occur as a “third hit” further 
reducing the activity of the attenuated germline mutant allele. We did not find 
any evidence for third hits affecting APC in duodenal adenomas. Instead, this 
change and the others clustering after the 3rd 20 AA repeat are likely to be 
selected for as second hits in duodenal tumorigenesis because they 
determine a specific level of β-catenin signaling that is lower than that 
selected for in colorectal tumorigenesis. A subtly different β-catenin signaling 
requirement in duodenal adenomas may also explain the absence of WTX 
mutations.  
 
In addition to APC and KRAS, 10 of the 13 other genes that were mutated 
significantly upon whole exome sequencing of duodenal adenomas are also 
mutated significantly in the COSMIC database of somatic mutations in cancer 
(Table 2). These genes are likely to be drivers in FAP and MAP duodenal 
tumors as well as in other tumor types. Following whole exome sequencing 
we investigated the recurrently mutated genes PTCHD2, ERBB3 and PLCL1 
in a set of 42 additional duodenal adenomas. We identified further mutations 
in PTCHD2 (N = 3) and PLCL1 (N = 2), supporting a role for these genes as 
drivers in duodenal tumorigenesis. PLCL1 encodes a multivalent adaptor 
protein (46). Four of six mutations identified in this study were missense 
changes clustered around the X-Box region of the PLC core domain. A 
truncating mutation of PLCL1 (S931X) was also identified in 1 of 14 colorectal 
adenoma exomes in the study of Rashid et al (20). PTCHD2 (DISP3) has 
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been assigned to the family of Patched-domain containing receptors based on 
in silico characterization and is likely involved in Hedgehog signaling (47).  
 
A number of genes such as MLL3 and ATRNL1 in which we identified only 
single truncating mutations were also mutated recurrently in FAP and/or MAP 
colorectal adenomas in other recent studies (20). They represent candidate 
driver genes in duodenal as well as colorectal tumorigenesis. aCGH identified 
CNVs exclusively in MAP duodenal adenomas and several included genes 
(SMAD4, ENG and GREM1) that regulate BMP signaling and have 
established roles in gastrointestinal cancer. aCGH lacks sensitivity in the 
context of heterogeneous tumor samples that comprise a mixture of 
neoplastic and non-neoplastic cells and we are likely to have underestimated 
the true frequency of CNVs. Pathway enrichment analysis of all validated 
mutations provided an approach to evaluate the potential roles of multiple 
genes with related functions. It highlighted involvement of Wnt, ERBB, 
PI3K/AKT, EGF, FGF and ECM-receptor signaling in FAP adenomas and of 
DNA repair pathways and epigenetic transcription regulators in MAP 
adenomas. Dysregulation of these pathways is well established in 
tumorigenesis and they are targets for drugs in clinical use or under 
development. So far only EGF signaling has been targeted in clinical trials for 
duodenal polyposis (16). Our data point to additional and novel opportunities 
for intervention but they also highlight the molecular genetic heterogeneity of 
duodenal adenomas. Only genes that regulate the Wnt pathway were mutated 
consistently. The highly specific and restricted pattern of APC mutation and 
the absence of WTX mutation that we observed in duodenal adenomas 
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suggest that a narrow range of β-catenin activity may be required for 
duodenal tumorigenesis. Therapeutic manipulation of this activity may hold 
particular promise for prevention and treatment. 
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Figure Legend 
 
Figure 1. Box plot showing per megabase (Mb), median and 25th and 75th 
percentiles and range of confirmed non-synonymous SNVs in FAP and MAP 
duodenal adenomas.   
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Tables and Figures 
Table 1. Details of patients and adenomas studied. Adenomas with IDs in gray boxes were subject to whole exome sequencing. TA 
= tubular adenoma, TVA = tubulovillous adenoma, VA = villous adenoma, LGD = low grade dysplasia. Non-independent adenomas 
are shown in bold. Total numbers of adenomas were counted following chromoendoscopy. 
Patient Adenoma Germline Mutation Somatic APC mutation(s) FAP/ MAP 
Age 
(years) 
Patient 
Sex 
Total 
Number of 
Adenomas* 
Size of 
adenoma 
(mm) 
Histology 
% 
Adeno-
matous 
Tissue 
Spigel-
man Stage 
2 2A5 c.994C>T; p.R332X None identified FAP 43 M 1 2 TA LGD 40% I 
3 
3A2 
APC Promoter-Exon 2 Deletion 
None identified 
FAP 38 F 38 
5 TA LGD 40% 
III 3A3 4645 C>T Q1549X 5 TA LGD 90% 
3A4 4659dupA E1554fsX5 6 TA LGD 30% 
4 
4A1 
APC Promoter-Exon 2 Deletion 
None identified 
FAP 69 M 21 
3 TA LGD 50% 
II 4A2 None identified 3 TA LGD 50% 
4A3 None identified 4 TA LGD 50% 
8 8A2 c.477C>G; p.Y159X 4348 C>T R1450X FAP 36 M 6 2 TA LGD 40% II 8A3 4645 C>T Q1549X 3 TA LGD 50% 
17 
17A1 
APC Exon 4_5 Deletion 
4612_4613delGA E1538IfsX5 
FAP 38 F 79 
15 TA LGD 80% 
IV 17A2 4691 T>G L1564X 20 TVA LGD 80% 
17A3 None identified 5 TA LGD 40% 
19 
19A1 
c.2805C>A; p.Y935X 
4659dupA E1554fsX5 
FAP 35 M 61 
15 TVA LGD 10% 
IV 19A2 4659dupA E1554fsX5 8 TA LGD 30% 19A3 4659dupA E1554fsX5 10 TA LGD 20% 
19A4 4729 G>T E1577X 12 TA LGD 5% 
21 21A1 c.3785 dupA; p.Y1262FfsX2 4659dupA E1554fsX5 FAP 41 F 110 30 TVA LGD 80% IV 21A3 4659dupA E1554fsX5 5 TA LGD 20% 
22 
22A2 
c.3366_69delTCAA; p.N1122fsX2 
4659dupA E1554fsX5 
FAP 32 F 8 
2 TA LGD 30% 
II 22A3 None identified 4 TA LGD 10% 
22A4 4381G>T E1461X 4 TA LGD 60% 
23 23A1 c.477C>G; p.Y159X 4659dupA E1554fsX5 FAP 45 F 16 2 TA LGD 10% II 23A2 4659dupA E1554fsX5 4 TA LGD 60% 
29 
29A2 
c.3203_3205delTCAA; p.S1068fsX56 
4698 del23bp D1566fsX16 
FAP 53 M 14 
4 TA LGD 5% 
IV 29A3 4659dupA E1554fsX5 4 VA LGD 40% 
29A4 4659dupA E1554fsX5 5 TVA LGD 35% 
30 30A1 c.3198 ACAAT>CAAT; p.R1067fsX59 4659dupA E1554fsX5 FAP 49 F 26 4 TA LGD 50% III 30A3 4592dupA N1531KfsX2 8 TA LGD 40% 
50 50A1 c.637C>T; p.Arg213X None identified FAP 31 F 2 2 TA LGD 50% I 50A2 None identified 1 TA LGD 50% 
51 
51A1 
c.637 C>T; p.R213X 
4606 G>T E1536X 
FAP 42 M 17 
10 TA LGD 50% 
III 51A3 4659dupA E1554fsX5 4 TA LGD 30% 
51A4 LOH (nt5037) 2 TA LGD 20% 
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51A5 None identified 2 TA LGD 5% 
52 
52A1 
c.3863 GA>A; p.G1288fsX16 
3862delG G1288fsX17 
FAP 37 M 5 
6 TA LGD 50% 
IV 
52A2 4734 T>A C1578X 8 TA LGD 50% 
52A3 4659dupA E1554fsX5 25 TVA LGD 80% 
52A4 4348 C>T R1450X 15 TA LGD 60% 
52A5 4393_4394dupAG S1465RfsX9 6 TVA LGD 60% 
D1 D1A1 c.3203-3205delTCAA None identified FAP 56 M 20 3 TA LGD 30% II D1A2 None identified 3 TA LGD 20% 
D4 D4A3 c.3176_3180delAAATA; p.I1060TfsX3 4722_4725delACTA I1574MfsX75 FAP 29 M 10 10 TA LGD 60% II 
7 7A2 c.536A>G; p.Y179C (HOM) 4735 G>T E1560X MAP 62 F 1 1,5 TALGD 40% I None identified 
24 
24A1 
c.536 A>G; p.Y179C (HOM) 
4678 G>T E1560X 
MAP 59 M 15 
15 TA LGD 40% 
III 
LOH (rs2019720) 
24A2 4381 G>T  E1461X 10 TA LGD 40% 4654 G>T E1552X 
24A3 3502 G>T E1168X 15 TA LGD 50% 4654 G>T E1552X 
24A4 3502 G>T E1168X 8 TA LGD 50% 4654 G>T E1552X 
24A5 2281 G>T E761X 6 TA LGD 10% None identified  
24A6 4639 G>T E1547X 5 TA LGD 20% None identified  
24A7 2863 G>T E955X 15 TVA LGD 70% 4612G>T E1538X 
24A8 3502 G>T E1168X 12 TVA LGD 90% 4654 G>T E1552X 
26 26A1 c.1438 G>T; p.E480X (HOM) None identified  MAP 51 F 1 5 TA LGD 60% II 4639 G>T E1547X 
33 
33A1 
c.1438 G>T; p.E480X (HOM) 
None identified 
MAP 68 F 2 
3 TA LGD 50% 
I 
33A2 None identified 3 TA LGD 50% 
36 
36A1 
c.1438 G>T; p.E480X (HOM) 
2962 G>T E988X 
MAP 65 F 3 
3 TA LGD 50% 
II 4639 G>T E1547X 
36A3 3845 C>A S1282X 8 TA LGD 50% 4726 G>T E1576X 
37 
37A1 
c.1214 C>T; p.P405L and c.1187 G>A; 
p.G396D 
526 G>T E176X 
MAP 66 F 2 
25 TA LGD 40% 
II 4659dupA E1554fsX5 
37A4 526 G>T E176X 25 TA LGD 70% 4659dupA E1554fsX5 
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38 
38A1 
c.739 T>C; p.R247X and c.536 G>A; 
p.Y179C 
4381G>T E1461X 
MAP 47 M 4 
5 TA LGD 30% 
II 
None identified  
38A2 3460 G>T E1154X 5 TA LGD 30% 4381 G>T  E1461X 
38A3 4381G>T E1461X 5 TA LGD 50% 3460 G>T E1154X 
38A5 4381G>T E1461X 5 TA LGD 50% 3460 G>T E1154X 
39 
39A1 
c.1438 G>T; p.E480X (HOM) 
4639 G>T E1547X 
MAP 49 F 3 
9 TA LGD 40% 
II None identified  
39A3 LOH (D5S346) 9 TA LGD 40% None identified  
41 
41A2 
c.1438 G>T; p.E480X (HOM) 
None identified  
MAP 54 F 2 
5 TA LGD 80% 
II 
41A3 None identified  4 TA LGD 10% 4729 G>T E1577X 
44 
44A1 
c.1240 C>T; p.Q414X (HOM) 
None identified  
MAP 42 M 4 
5 TA LGD 60% 
II 
4639 G>T E1547X 
44A2 2311 G>T E771X 5 TA LGD 60% 4630 G>T E1544X 
44A4 4588 G>T E1530X 4 TA LGD 60% 3406 G>T E1136X 
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Table 2. Significantly mutated genes identified by MutSig analysis of mutations in Supplementary Table 3 and COSMIC. Every 
mutation was assigned a CADD score to assess potential functional impact and deleteriousness (Suppl methods). Variants shaded 
in light gray were present in only MAP adenomas, variants in white were present only in FAP adenomas and those shaded in dark 
gray were detected in both FAP and MAP adenomas. An asterisk denotes variants that were identified more than once with a 
superscript number to designate the number of times the variant was detected. 
Rank 
(#) Gene Chr 
Genomic 
location Ref Alt 
Predicted 
protein 
Number 
of 
variants 
P value  FDR (q) P value (COSMIC) 
FDR (q) 
(COSMIC) 
Significantly recurrently 
mutated in COSMIC (P < 
0.05 & q <= 0.1) 
CADD 
PHRED 
1 APC 
5 112111429 G T E176X 
24 4.33E-17 2.68E-15 1.69E-103 3.49E-102 TRUE 
41 
5 112173602 G T E771X 39 
5 112174253 G T E988X 39 
5 112174697 G T E1136X 39 
5 112174793 G T E1168X 39 
5 112175136 C A S1282X 37 
5 112175672 G T E1461X 37 
5 112175897 G T E1536X 42 
5 112175921 G T E1544X 39 
5 112175945 G T E1552X 39 
5 112175951 *4 G GA E1554fsX5 33 
5 112175969 G T E1560X 41 
5 112175982 T G L1564X 38 
5 112176017 G T E1576X 43 
5 112176025 T A C1578X 36 
5 112174751 G T E1154X 38 
5 112175879 *2 G T E1530X 42 
5 112175930 G T E1547X 42 
5 112175879 G GA N1531KfsX2 35 
5 112175639 C  T R1450X 38 
2 PIGA 
X 15343189 C T E78K 
4 8.16E-05 2.53E-03 7.80E-01 1.00E+00 FALSE 
33 
X 15342923 G T P116H 43 
X 15342994 C T SPLICE 25.9 
X 15349456 AT A N199fsX4 30 
3 SLC4A3 2 220500412 *3 G A G691R 3 1.66E-04 3.43E-03 2.38E-07 1.23E-06 TRUE 21.8 
4 KRAS 
12 25398284 C T G12D 
4 4.79E-04 5.94E-03 0.00E+00 0.00E+00 TRUE 
25.3 
12 25398285 *2 C A G12C 33 
12 25398285 C T G12S 31 
5 OR51T1 11 4903600 C A F157L 2 6.71E-04 5.94E-03 7.75E-06 3.45E-05 TRUE 0.074 11 4904017 G T L296F 25.3 
6 FLG2 1 152325661 G T S1534Y 2 6.71E-04 5.94E-03 7.82E-25 9.70E-24 TRUE 23.2 1 152329718 G T H182N 0.92 
Research. 
on August 11, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
 36 
7 RBMXL3 X 114425545 G A R514Q 2 6.71E-04 5.94E-03 8.40E-09 4.73E-08 TRUE 21.2 X 114424797 G T G256C 1.495 
8 TRAM1L1 4 118005732 C A G273V 2 1.98E-03 1.36E-02 4.24E-03 1.31E-02 TRUE 23.5 4 118005846 A G M235T 0.076 
9 KRT5 12 52914023 C T A20T 2 1.98E-03 1.36E-02 7.80E-06 3.45E-05 TRUE 1.001 12 52910917 C A A398S 23.1 
10 SFTPD 10 81706265 C T R50C 2 3.89E-03 2.29E-02 1.64E-02 4.61E-02 TRUE 24.5 10 81706268 G A D51Y 24.8 
11 IGFN1 1 201181973 *3 C T S69F 3 4.07E-03 2.29E-02 1.14E-01 3.06E-01 FALSE 23.3 
12 CYLC1 X 83128944 G T E410X 2 1.29E-02 6.68E-02 7.35E-05 2.68E-04 TRUE 39 X 83128633 C A A306D 0.038 
13 PTCHD2 
1 11561594 G T G182S 
3 1.85E-02 8.80E-02 1.11E-02 3.28E-02 TRUE 
0.018 
1 11584030 G T Q798H 22.5 
1 11591019 G T C1035F 27.6 
14 ERBB3 12 56480320 C A L143M 2 2.14E-02 8.86E-02 5.36E-05 2.08E-04 TRUE 28.4 12 56487261 C G N469K 30 
15 NONO X 70514194 C A P156T 2 2.14E-02 8.86E-02 4.45E-01 1.00E+00 FALSE 13.24 X 70514212 G A E162K 33 
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Table 3. Summary of somatic analyses completed including exome analysis, arrayCGH, APC LOH analysis and targeted 
sequencing of APC, KRAS, WTX, PTCHD2, ERBB3 and PLCL1. * Analysis completed but no mutation identified.  Mutation 
identified by exome sequencing.  LOH or CNV detected.  Mutation detected by targeted sequencing. A blank well denotes 
where a sample was not analysed. Non-independent adenomas are shown in bold, totals reflect the duplication. Gray shading 
denotes samples that underwent exome sequencing. The table is split to represent the analyses completed on the FAP adenomas 
in the first section followed by the MAP adenomas in the lower section. The total number of samples screened and mutations 
detected is given for both the FAP and MAP adenomas individually and then summed across the whole cohort at the end of the 
table.  
Adenoma Sample FAP/MAP Exome Sequencing 
APC 
Sequencing 
WTX 
Sequencing 
KRAS 
Sequencing 
PLCL1 
Sequencing 
PTCHD2 
Sequencing 
ERBB3 
Sequencing APC LOH ArrayCGH 
17A1 
FAP 
 
 * * * * * * * 
17A2 
 
 * *  * * 
 
* 
30A1 
 
 * * * * * 
 
* 
30A3 
 
 * * * * * * * 
51A1 
 
 * *  * * 
 
* 
51A3 
 
 * * * * * 
 
* 
51A4 
 
* * * * * *  * 
52A2 
 
 * * * * * * * 
52A3 
 
 * * * * * 
 
* 
52A4 
 
 *  * *  
 
* 
2A5 
 
* * * * * * * 
 
3A2 
 
* * * *  * * * 
3A3 
 
 * * * * * 
 
* 
3A4 
 
 * * * * * 
  
4A1 
 
* *  * * * * * 
4A2 
 
* * * * * * * 
 
4A3 
 
* * * * * * * * 
8A3 
 
 * *  * * 
 
* 
19A1 
 
 * * * * * 
 
* 
19A2 
 
 * * * * * 
 
* 
19A3 
 
 * * * * * 
 
* 
19A4 
 
 * * *  * 
 
* 
21A3 
 
 * * * * * 
  
22A2 
 
 * * * * * 
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22A3 
 
* * * * * * * 
 
22A4 
 
 * * * * * 
 
* 
23A1 
 
 * * * * * 
  
23A2 
 
 * * * * * 
 
* 
29A2 
 
 *  * * * 
  
29A3 
 
 *  * * * 
 
* 
29A4 
 
 * * * * * 
  
50A1 
 
* * * * * * * 
 
50A3 
 
* * * * * * * 
 
51A5 
 
* * * * * * * 
 
52A1 
 
 * * * * * 
  
D1A1 
 
* * * * * * * 
 
D1A2 
 
* * * * * * * 
 
D4A3 
 
* * * * * * * 
 
8A2 
 
 
      
* 
17A3 
 
* 
     
* * 
21A1 
 
 
      
* 
52A5 
 
 
      
* 
FAP adenomas analysed 
 
10 42 38 38 38 38 38 17 26 
FAP adenomas with mutations 
 
n/a 28 (66.6%) 0 4 (10.5) 3 (7.9%) 2 (5.2%) 1 (2.6%) 1 (5.9%) 0 
           
Adenoma Sample FAP/MAP Exome Sequencing 
APC 
Sequencing 
WTX 
Sequencing 
KRAS 
Sequencing 
PLCL1 
Sequencing 
PTCHD2 
Sequencing 
ERBB3 
Sequencing APC LOH ArrayCGH 
24A1 
MAP 
 
 * * * * *  * 
24A3 
 
 *  * *  
 
 
24A8 
 
 *  * *  
 
* 
36A1 
 
 * * * * * * * 
36A3 
 
 * * * * * 
 
* 
37A1 
 
 *    * 
 
 
37A4 
 
 *   * * 
 
* 
38A2 
 
 *  *  * 
 
 
44A2 
 
 * * * * * 
 
 
44A4 
 
 * * * * * 
 
* 
7A2 
 
 * * * * * 
 
* 
24A2 
 
 * * * * * 
  
24A4 
 
 *  * * * 
 
 
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24A5 
 
 * * * * * 
 
* 
24A7 
 
 * * * * * 
  
26A1 
 
 * * * * * 
 
* 
33A1 
 
* * * * * * * 
 
33A2 
 
* * * * * * * 
 
38A3 
 
 *  * * * 
  
38A5 
 
 *  * * * 
  
39A1 
 
 *   * * 
 
* 
39A3 
 
* * * * * *  * 
41A3 
 
 * * * * * 
 
* 
44A1 
 
 *  * * * 
 
* 
24A6 
 
 
      
* 
41A2 
 
* 
     
* * 
38A1 
 
 
      
* 
MAP adenomas analysed 
 
10 27 24 24 24 24 24 6 21 
MAP adenomas with mutations 
 
n/a 21 (77.8%) 0 8 (33.3%) 2 (8.3%) 2 (8.3%) 1 (4.2%) 2 (33.3%) 5 (23.8%) 
           
Number of adenomas analysed 
 
20 69 62 62 62 62 62 23 47 
Adenomas with mutations 
 
n/a 49 (71%) 0 12 (19.4%) 5 (8.1%) 4 (6.5%) 2 (4.8%) 3 (13%) 5 (10.6%) 
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Table 4. Summary of Copy Number Variants (CNVs) detected by array CGH. 
 
Adenoma FAP/MAP Location CNV Start End Size (bp) OMIM Genes HGNC Genes 
24A3 
MAP 
15q11.1-15q21.1  GAIN 20.071.673 48.342.606 28.238.748 134 375 
24A4 15q11.1-15q21.1  GAIN 20.071.673 48.342.606 28.238.748 134 375 
37A1 8p23.1  DEL 6.805.940 9.615.505 2.809.566 15 74 9q22.32 DEL 99.121.641 131.163.638 32.041.998 153 293 
38A2 7p22.3 - 7q36.3 GAIN 54.215 157.723.016 157.668.802 589 1.243 
44A2 
8p23.1  DEL 7.691.931 8.046.302 354.372 3 15 
18p11.32 DEL 148.993 9.371.093 9.222.101 24 38 
18q21.1 DEL 47.594.529 78.012.800 30.418.272 70 104 
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Figure 1. 
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